BioSpace News Archive

Karolinska Development’s portfolio company Forendo Pharma announces today that Vesalius Biocapital III Partners (Vesalius) joins Forendo Pharma’s existing international investor syndicate.

Forendo Commences Phase Ia Study for FOR-6219 for Endometriosis

Seventure Partners today announces its corporate update for the period May-August 2018.

Inoviem Scientific today announces a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases. Financial terms of the partnership were not disclosed.

Fibrocell Science, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma

Proceeds will advance clinical development of PB2452, a potentially first-in-class reversal agent for patients on ticagrelor, and PB1046, a novel treatment for PAH

Loxo Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-292

In testimony before the U.S. House Energy and Commerce Subcommittee on Health today, pharmacist-owner Hugh M. Chancy urged support for draft legislation to prohibit restrictive contractual language, often referred to as “gag clauses,” that may result in patients being charged inflated prices for their medications.

BioChaperone® Pramlintide Insulin (BC Pram Ins) is the first product to clinically demonstrate the feasibility of a fixed-ratio co-formulation of pramlintide and human insulin

National Institute for Innovation in Manufacturing Biopharmaceuticals Funds UMB Researcher